Results from the Phase 3 VISIONARY trial showed a 97.1% reduction in the risk of a composite kidney outcome event of kidney ...

Otsuka is a healthcare company driven by our purpose and defined by our beliefs.

Ulefnersen demonstrated a statistically significant improvement versus placebo on the primary endpoint assessing functional impairment and survival in people living with FUS-ALS, supporting the ...

For individuals navigating investigational treatment options with their healthcare providers, understanding available access pathways can be complex. While participation in a clinical trial is ...

New Phase 3b results demonstrated consistent improvements with centanafadine across ADHD and anxiety symptoms, executive function and emotional dysregulation, as assessed by both clinicians and ...

SIMTRIYO is the first and only norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) approved for the treatment of ADHD in adults and pediatric patients aged 6 years and older weighing at ...

Study met its primary endpoint, demonstrating statistically significant and clinically relevant improvements in ADHD symptoms in adults with ADHD and comorbid anxiety taking centanafadine compared to ...

Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents, and adults. It is a novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). The ...

PRINCETON, N.J. and TOKYO, JAPAN – November 25, 2025 – Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) today announce the U.S. Food and Drug ...

Phase 3 VISIONARY study met its primary endpoint at the prespecified interim analysis; sibeprenlimab demonstrated a statistically significant and clinically meaningful reduction in 24-hour uPCR after ...

Nationwide Well Beings Campaign Leverages Power of Public Media, Collaborators, and Extended Digital Series to Highlight Caregiving Challenges and Advances In the U.S., more than 53 million family ...